PMID- 10506612
OWN - NLM
STAT- MEDLINE
DCOM- 20000104
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 17
IP  - 10
DP  - 1999 Oct
TI  - Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 
      in laryngeal cancer.
PG  - 3150-9
AB  - PURPOSE: To investigate the prognostic relevance of p21 and p27 protein 
      expression in laryngeal squamous cell carcinoma (LSCC). PATIENTS AND METHODS: We 
      have analyzed by immunohistochemistry p21 and p27 expression in a series of 132 
      patients who underwent surgical resection of their LSCC and who had previously 
      been investigated for p53 gene mutations and cyclin D1 expression. The tumors 
      were considered low expressors when they had </= 10% of p21 and </= 50% of p27 
      immunoreactive neoplastic cells. RESULTS: In 41 cases (31.1%), p21 was expressed 
      in </= 10% of neoplastic cells; in 91 cases (68.9%), it was expressed in more 
      than 10% of neoplastic cells. In 11 cases (8.3%), p27 was expressed in less than 
      5% of neoplastic cells; in 39 cases (29.6%), it was expressed in 5% to 50% of 
      neoplastic cells; and in 82 cases (62.1%), it was expressed in more than 50% of 
      the neoplastic cells. Low levels of p21 expression were associated with poor 
      histologic differentiation and lymph node metastases. Low levels of p27 
      expression were associated with tumor extension and advanced clinical stage. 
      Expression of p21 and p27 was not correlated with p53 gene status, and low p27 
      expression was more frequently detected in the cyclin D1-positive cases, with a 
      borderline level of statistical significance. At univariate analysis, anatomic 
      site, tumor extension, clinical stage, high cyclin D1 expression, and low p27 
      expression were significantly associated with reduced disease-free and overall 
      survival rates. At multivariate analysis, high cyclin D1 expression and low p27 
      expression were the only significant covariates. The patients with a cyclin 
      D1(+)/p27(-) phenotype had the poorest disease-free and overall survival rates. 
      CONCLUSION: Our study provides evidence that the immunohistochemical evaluation 
      of p27 expression is a significant independent predictor of prognosis in 
      laryngeal carcinoma.
FAU - Pruneri, G
AU  - Pruneri G
AD  - II Servizio di Anatomia Patologica, Clinica Otorinolaringoiatrica I, Laboratorio 
      Epidemiologico, Istituto di Scienze Mediche, Universita di Milano, Ospedale 
      Maggiore di Milano, Milan, Italy.
FAU - Pignataro, L
AU  - Pignataro L
FAU - Carboni, N
AU  - Carboni N
FAU - Buffa, R
AU  - Buffa R
FAU - Di Finizio, D
AU  - Di Finizio D
FAU - Cesana, B M
AU  - Cesana BM
FAU - Neri, A
AU  - Neri A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Cyclins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Cell Cycle
MH  - *Cell Cycle Proteins
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Cyclin-Dependent Kinase Inhibitor p27
MH  - Cyclins/biosynthesis/*genetics
MH  - Disease-Free Survival
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Male
MH  - Microtubule-Associated Proteins/biosynthesis/*genetics
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Tumor Suppressor Proteins
EDAT- 1999/10/03 00:00
MHDA- 1999/10/03 00:01
CRDT- 1999/10/03 00:00
PHST- 1999/10/03 00:00 [pubmed]
PHST- 1999/10/03 00:01 [medline]
PHST- 1999/10/03 00:00 [entrez]
AID - 10.1200/JCO.1999.17.10.3150 [doi]
PST - ppublish
SO  - J Clin Oncol. 1999 Oct;17(10):3150-9. doi: 10.1200/JCO.1999.17.10.3150.